Marker Therapeutics Provides Business and Clinical Update
March 28, 2019
—MultiTAA T cell therapies continue to demonstrate positive clinical data across multiple indications in investigator-sponsored trials—
—Marker plans IND submission for Company-sponsored Phase 2 AML study in the third quarter, with first patient enrolled by the end of 2019—
—First update in the solid tumor program planned for second quarter—
—Company to host business update call and webcast today at 5:00 p.m. EDT—[/vc_column_text][vc_column_text]Houston, TX –March 28, 2019– Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a business and clinical update, as well as an overview of upcoming milestones for 2019. “Our MultiTAA T cell therapies have continued to generate positive and compelling clinical data across various indications in several ongoing investigator-sponsored clinical trials led by Baylor College of Medicine (BCM). We plan to advance a Phase 2 Company-sponsored clinical trial in post-transplant acute myeloid leukemia (AML)—a disease area and patient population for which there are limited treatment options. We expect to finalize our clinical trial protocol in AML by the end of the second quarter of 2019 and to submit our IND in the third quarter, with the first patient enrolled by the end of the year,” said Peter L. Hoang, President & CEO of Marker Therapeutics. Continued Mr. Hoang: “While our T cell therapies remain our primary clinical focus, we are also advancing our T cell vaccine candidates, TPIV200 and TPIV100/110, for the treatment of ovarian and breast cancers. Overall, there are two Phase 2 Company-sponsored studies ongoing for TPIV200 in triple-negative breast cancer and ovarian cancer, and we anticipate reporting interim data from the ovarian cancer Phase 2 study in Q4 2019.” PROGRAM HIGHLIGHTS AND CURRENT UPDATES Multi-Antigen Targeted (MultiTAA) T Cell Therapies Acute Myeloid Leukemia Data
- The Company reported a clinical update from a Phase 1 clinical trial in post-transplant AML in oral and poster presentations at ASH in December and ASBMT and CIBMTR in February. Results from the BCM-sponsored study showed that the treatment is safe and well-tolerated and has the potential to mediate a meaningful anti-tumor effect, as well as significant in vivoexpansion of T cells. Among the highlights from the study, 11 out of 13 patients dosed with MultiTAA T cells as a maintenance therapy after receiving allogeneic stem cell transplant remain alive, ranging from 6 weeks to 2.5 years post-infusion. Nine of these patients have never relapsed after MultiTAA therapy and continue to remain in complete remission (CR). Patients with active disease, overall survival ranged from 4 and 21 months as compared to 4.5 months in historical results after standard of care.
- Marker will pursue post-transplant AML as the lead indication of its T cell therapy program. Based on findings from various dose cohorts in the Phase 1 BCM-sponsored trial, Marker has made a strategic decision to focus on post-transplant AML, and plans to initiate pre-IND discussions with the U.S. FDA in the second quarter of 2019, with an IND submission for the Company-sponsored potentially pivotal Phase 2 study in the third quarter. The multicenter study will evaluate clinical efficacy of MultiTAA specific T cells in patients with AML or myelodysplastic syndromes (MDS) in both the adjuvant and active disease setting, following an allogeneic hematopoietic stem cell transplant (HSCT). The dose administered will be the maximum tolerated dose from the BCM-sponsored Phase 1 trial. In the adjuvant setting, patients will be randomized 2:1 to either MultiTAA therapy at approximately 90 days post-transplant versus standard of care observation, while the active disease patients will receive MultiTAA T cells as part of a single-arm group.
- To date, no relapses have been observed for any patient entering a complete response (CR);
- Patients with active disease are now between 1 and 5+ years in CR after infusion of MultiTAA cells (ongoing);
- Several patients with stable disease show potential durable disease stabilization, with two patients experiencing stable disease for over 9 months and 24 months, respectively;
- Responses in all six patients who entered CR were associated with an expansion of infused T cells, as well as induction of antigen spreading.
- Patients are now up to 28 months in continued complete remission (CCR);
- The one patient who experienced relapse displayed mixed donor/recipient chimerism after transplant, but remained in CCR for 6 months;
- Patients who remain in CCR have been durable for between 4 to 28 months, with a median of 16 months.
- One patient with a CR durable for approximately 29 months before relapse, was subsequently given a second treatment infusion of MultiTAA T cells, resulting in stable disease for 3 months (ongoing) after the second treatment;
- Two patients achieved partial responses (PR) of between 14 and 22 months (ongoing) as of last follow-up;
- All seven remaining patients experienced stabilization of disease following infusion of MultiTAA cells initially. Three patients developed transient disease stabilization of between 3-7 months with subsequent progression, and four patients have ongoing stable disease.
- Eight patients were treated in remission, with a median follow-up of 21 months. Only one patient has relapsed to date;
- Correlative studies show significant expansion of MultiTAA T cells, as well as significant evidence of epitope spreading with expansion of endogenous T cells specific for tumor-associated antigens that were not targeted by the MultiTAA product.
- As the Company reported in January, 2019, it has completed enrollment in its Phase 2 study in ovarian cancer using TPIV200 as a maintenance therapy for patients in their first remission after surgery and platinum-based chemotherapy. To date, Marker has enrolled, randomized, and treated 120 patients at 17 clinical sites. The study completed enrollment six months faster than anticipated and the Company expects to reach its planned interim analysis trigger of 55 patients who have progressed before the end of 2019.
- The Company also reported initial findings from its interim analysis of its dose-finding study in triple negative breast cancer, using TPIV200 as a maintenance therapy for patients in remission following first-line therapy. The four-arm study included low- and high-dose TPIV200 with or without cyclophosphamide. Of 27 patients evaluated to date for immunogenicity, 26 showed significant immune response to the vaccine treatment. Of 80 patients treated at 11 clinical sites, 11 have shown disease progression to date following treatment with TPIV200.
- Pre-IND discussions for AML with the U.S. FDA in Q2;
- First update in solid tumor program in Q2 concurrently with a major medical meeting;
- IND submission for Company-sponsored Phase 2 AML study in Q3, with first patient enrolled by end of 2019;
- Interim analysis readout in the TPIV200 ovarian trial in Q4;
- Overall update on ongoing clinical trials in cell therapy at end of 2019.